Држава: Канада
Језик: Енглески
Извор: Health Canada
CLARITHROMYCIN
PHARMASCIENCE INC
J01FA09
CLARITHROMYCIN
500MG
TABLET
CLARITHROMYCIN 500MG
ORAL
100/250
Prescription
OTHER MACROLIDES
Active ingredient group (AIG) number: 0123752002; AHFS:
APPROVED
2007-08-10
_pms-CLARITHROMYCIN (clarithromycin) _ _Page 1 of 80_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PMS-CLARITHROMYCIN Clarithromycin Tablets, USP Film-Coated Tablets, 250 mg and 500 mg, Oral USP Antibiotic NOTE: WHEN USED IN COMBINATION WITH ACID ANTISECRETORY DRUGS AND OTHER ANTIMICROBIALS FOR THE ERADICATION OF _HELICOBACTER PYLORI_, THE PRODUCT MONOGRAPH FOR THOSE AGENTS SHOULD BE CONSULTED. PHARMASCIENCE INC. 6111 Royalmount Ave, Suite #100 Montréal, Québec, H4P 2T4 www.pharmascience.com Submission Control Number: 259932 Date of Initial Authorization AUG 10, 2007 Date of Revision: May 5, 2022 _pms-CLARITHROMYCIN (clarithromycin) _ _Page 2 of 80_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 05/2022 7 WARNINGS AND PRECAUTIONS; 7.1.1 Pregnant Women; 7.1.2 Breast-feeding 05/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES..............................................................................................2 TABLE OF CONTENTS ................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 1 INDICATIONS ......................................................................................................................4 1.1 Pediatrics ................................................................................................................5 1.2 Geriatrics.................................................................................................................5 2 CONTRAINDICATIONS .........................................................................................................5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ....................................................................7 4 DOSAGE AND ADMINISTRATION ........................................................................................7 4.1 Dosing Co Прочитајте комплетан документ